Atypical antidepressant
Tianeptine
Tianeptine's mean elimination half-life in healthy volunteers is reported as 2.5 ± 1.1 hours, the same as the app's figure of 2.5 hours.1
Tianeptine after one dose: 50% at ~2.5 h, 25% at 5 h, 12.5% at 7.5 h.
Drawn from the half-life in the app's model, ~2.5 h. The model's figures
- Compound
- Tianeptine
- Symbol
- TIA
- Family
- Supplements
- Parts
- 13
- References
- 15
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Tianeptine is described in a 2001 review by Wagstaff and colleagues as "an antidepressant agent with a novel neurochemical profile".2 A 2024 chemistry review by Nishio and colleagues states that, after an increase in cases of use in the United States, "some states have banned products" containing tianeptine and designated it a Schedule I or II controlled substance.3 The US Food and Drug Administration states that tianeptine "is not approved by the FDA for any medical use".4 The app files tianeptine as a supplement-category atypical antidepressant and grades its evidence as anecdotal. The app's notes describe it as a μ-opioid agonist at recreational doses with high addiction liability.
How it works
Gassaway and colleagues at Columbia University reported in Translational Psychiatry in 2014 that tianeptine is an agonist at the μ-opioid receptor in binding and cell-based assays.5 The reported values were a Ki of 383±183 nM at the human receptor and EC50 values of 194±70 nM (human) and 641±120 nM (mouse) for G-protein activation.5 Tianeptine was also a full δ-opioid receptor agonist at much lower potency (EC50 of 37.4±11.2 μM at the human receptor) and was inactive at the κ-opioid receptor.5 Samuels and colleagues reported in mice, in Neuropsychopharmacology in 2017, that the acute and chronic antidepressant-like behavioral effects of tianeptine require the μ-opioid receptor.6 In the same mouse study, tianeptine produced opiate-like effects such as analgesia and reward, and the authors report that it "does not lead to tolerance or withdrawal"; this is an animal result.6 The paper's funding statement lists the Hope for Depression Research Foundation, NIH grants and other funders, and states that one author is a consultant for Servier and Lundbeck.6 Nishio and colleagues note that, unlike conventional tricyclic metabolism, tianeptine "is not primarily metabolized by cytochrome" P450 enzymes.3
Deeper analysis: Gassaway and colleagues, μ-opioid receptor study
The work used HEK-293T cells and tianeptine sodium salt, with radioligand binding at the receptors and bioluminescence resonance energy transfer assays for G-protein activation and cAMP accumulation, so every value above comes from cells, not from people.5 In a screen of more than 50 human receptors at 10 μM, "Tianeptine bound to hMOR, the only hit identified in the entire panel, with a Ki of 383±183 nM".5 The authors present the receptor finding as a hypothesis, writing that they "propose that activation of MOR (or dual activation of MOR and DOR) could be the initial molecular event" behind many of the drug's effects, and that evidence for antidepressant effects from μ-opioid activation "has only been suggestive".5 The saved text of the paper carries the statement "The authors declare no conflict of interest" and no funding statement was located in it; co-author Javitch is the sponsor-investigator of the registered tianeptine trial NCT04249596, whose entry says "Work in our laboratories has shown that tianeptine acts as a selective agonist of MOR".5,7
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~2.5 h
- Bioavailability
- 99%
- Typical dose
- 12.5–37.5 mg/day
- Route
- Oral
- Time to peak
- ~1 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~2.5 h | 2.5 ± 1.1 h in healthy volunteers after oral tablets (Royer and colleagues, 1988); terminal half-life of 2.5 ± 1.1 h after a single oral 12.5 mg dose of the sodium salt in 12 healthy volunteers, as summarised in a 2024 review1,3 |
| Bioavailability | 99% | Absolute bioavailability of 99 +/- 29% in healthy subjects given the tablet; the 2024 review adds that no single measured value was lower than 66%1,3 |
| Time to peak | ~1 h | Maximum plasma concentration by the first hour after dosing (0.94 +/- 0.47 h)1 |
| Peak concentration | Not in the app | 334 +/- 79 ng/mL in fasting healthy subjects after oral administration (Royer and colleagues); 283.13 ± 57.58 ng/mL for a generic 12.5 mg tablet and 272.50 ± 59.00 ng/mL for the branded reference in the 40 healthy Korean men who completed the study (Zheng and Kim, 2014)1,8 |
| Distribution | Not in the app | Apparent volume of distribution about 0.8 L/kg (0.77 +/- 0.31 L/kg) and protein binding averaging 93.8 +/- 2.4%1 |
| Metabolite MC5 | Not in the app | Peak of 63 ± 14 ng/mL, Tmax of 2.23 ± 0.42 h and a plasma elimination half-life of 7.2 ± 5.7 h in the 12-volunteer study summarised by the 2024 review3 |
| Renal failure and age | Not in the app | A 1-h prolongation of elimination half-life in renal failure and in the elderly1 |
| Duration of effect | 4 h | The records read for tianeptine report no duration of effect; the app also lists a longer duration of about 8 hours for a sulfate extended-release form in its notes |
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Costa e Silva and colleagues, Neuropsychobiology 19979 | Multicentre, randomised, double-blind, parallel-group, placebo-controlled | 126 out-patients with DSM-III-R major depression or bipolar disorder, depressed, MADRS of at least 25 | Tianeptine 25-50 mg/day (mean 37.5 mg/day) or placebo for 42 days after a 1-week placebo run-in | Better final MADRS scores with tianeptine in the intention-to-treat population; acceptability did not differ from placebo; a higher incidence of headaches with tianeptine |
| Kauer-Sant'Anna and colleagues, Journal of Psychopharmacology 201910 | Multicentre, double-blind, randomised, placebo-controlled maintenance trial after 8 weeks open-label | 161 participants with MADRS of at least 12; 69 responders randomised (36 tianeptine, 33 placebo), added to usual treatment | Adjunctive tianeptine 37.5 mg/day or placebo; 24-week double-blind phase | No differences in time to intervention or depression scores; better letter-number sequencing at the endpoint (p=0.014) |
| UPLIFT, NCT05686408, Tonix Pharmaceuticals, registry entry 202511 | Phase 2, randomised, quadruple-masked, placebo-controlled | 132 enrolled with major depressive disorder, aged 18 to 65 | TNX-601 ER 39.4 mg once daily or placebo for 6 weeks | Week 6 least-squares mean change from baseline in MADRS of -12.7 (SE 1.30) with TNX-601 ER (n=64) and -12.8 (SE 1.32) with placebo (n=68) |
| NCT04249596, Javitch (New York State Psychiatric Institute), registry entry 20267 | Phase 4, open-label, single group, no comparator; terminated | 38 started and 30 completed; adults with unipolar major depression who had failed at least two antidepressant trials | Tianeptine sodium 12.5 mg three times daily for 8 weeks | HAMD-24 outcome posted as -5.2 (SD 9.8) in the 30 completers; 7 responders and 6 remitters among them |
| Algera and colleagues, Anesthesiology 202212 | Two randomised, double-blind, placebo-controlled crossover studies | Healthy male and female volunteers: 8 given oral tianeptine, 15 given intravenous tianeptine | Oral 37.5, 50 and 100 mg before alfentanil; intravenous infusions to target 400 to 2,000 ng/mL during remifentanil | Neither route stimulated ventilation; intravenous tianeptine lowered ventilation to 9.6 ± 0.8 l/min against 15.0 ± 0.9 l/min with placebo (P = 0.001) |
Deeper analysis: Costa e Silva and colleagues, 1997
Costa e Silva and colleagues compared tianeptine with placebo in 126 depressed out-patients in a multicentre, randomised, double-blind, parallel-group study, after a 1-week placebo run-in.9 They report better efficacy of tianeptine in final MADRS scores in the intention-to-treat population, in patients treated for at least 14 days and in completers, at a mean dosage of 37.5 mg/day.9 The PubMed record gives no effect size, interval or p-value for these comparisons. On safety the record says "acceptability did not differ from that of placebo" and names headaches as the adverse event with a higher incidence on tianeptine.9 Funding, author ties to a sponsor and the authors' own limitations are not stated in the PubMed record.
Deeper analysis: Kauer-Sant'Anna and colleagues, 2019
Kauer-Sant'Anna and colleagues, working from the Hospital de Clínicas de Porto Alegre with collaborators in Canada, tested adjunctive tianeptine 37.5 mg/day in bipolar disorder in a multicentre, double-blind, randomised, placebo-controlled maintenance trial.10 Of 161 participants who entered with a MADRS of at least 12, 69 responded to eight weeks of open-label tianeptine and were randomised to adjunctive tianeptine (n=36) or placebo (n=33).10 The record says time to intervention for a mood episode was evaluated with Kaplan-Meier estimates and the log-rank test, and reports no difference between adjunctive tianeptine and placebo in it or in depression scores.10 The authors conclude that "Tianeptine was not more effective than placebo in the maintenance treatment of bipolar depression".10 The record reports one difference, better letter-number sequencing at the endpoint (p=0.014), which the authors call "preliminary evidence" of a pro-cognitive effect; it also lists overall functioning, biological rhythms, quality of life and serum brain-derived neurotrophic factor levels as assessed, with no results given for them.10 On safety the authors write that tianeptine "was well tolerated and not associated with higher risk for manic switch compared to placebo".10 The PubMed record lists the article type "Research Support, Non-U.S. Gov't" and gives no funder, author ties to a sponsor or stated limitations.10
Deeper analysis: UPLIFT (NCT05686408)
The ClinicalTrials.gov entry names Tonix Pharmaceuticals as lead sponsor with Rho, Inc. as collaborator, and lists the intervention TNX-601 ER with the other name "Tianeptine".11 The study enrolled 132 participants aged 18 to 65 with major depressive disorder, and the primary outcome was the change from baseline in MADRS total score at Week 6.11 The posted least-squares mean changes were -12.7 (standard error 1.30) with TNX-601 ER 39.4 mg and -12.8 (standard error 1.32) with placebo, so the primary outcome did not separate the groups.11 The posted secondary outcomes were least-squares mean changes at Week 6 in CGI-S of -1.0 (standard error 0.15) with TNX-601 ER and -1.2 (0.16) with placebo, and in the Sheehan Disability Scale of -5.8 (0.95) with TNX-601 ER and -7.3 (0.97) with placebo; lower scores indicate less severe illness or less impairment.11 No deaths were listed in either arm (0 of 64 and 0 of 68); serious events were listed for 2 of 64 on TNX-601 ER (terms seizure, generalized tonic-clonic seizure and syncope, one participant each) and 1 of 68 on placebo (dermatomyositis), and nausea for 7 of 64 against 3 of 68.11 The entry's overall officials list Gregory Sullivan, MD as study director at Tonix Pharmaceuticals, and its restrictive-agreement field reads "An industry standard NDA is in place with all investigators".11 The entry posts no p-value or interval for the comparison and states no limitations.11
Deeper analysis: NCT04249596
The entry describes an open-label, single-group phase 4 study with no masking, led by sponsor-investigator Jonathan A. Javitch, with Icahn School of Medicine at Mount Sinai and Stanford University as collaborators.7 It planned 75 adults aged 21 to 60 with unipolar major depression "who have failed at least 2 two adequate treatment trials with a standard antidepressant".7 The status is TERMINATED with the reason "Inadequate recruitment", and the results section says "Study was terminated early due to inadequate recruitment (38 of 75 target enrolled)".7 Among the 30 completers the HAMD-24 outcome is posted as -5.2 (SD 9.8), with 7 meeting the response definition of at least a 50% reduction and 6 the remission definition of a score of 10 or lower.7 There were no deaths among 38, and one serious event, "Depression worsening requiring hospitalization".7 Of the 38 who started, 8 did not complete the 8 weeks (5 by withdrawal by subject and 3 lost to follow-up), and the other adverse events listed were headache in 2 and somnolence in 3 of 38.7 With one arm and no masking, the entry offers no comparison with placebo, and its limitations field reads "Study terminated early due to inadequate recruitment (38 of 75 target enrollment). Open-label, single-arm design without placebo control."7
Deeper analysis: Algera and colleagues, 2022
Algera and colleagues at Leiden University Medical Center, with five authors affiliated with AMO Pharma Ltd and one with Numedicus Ltd, tested the hypothesis that "oral or intravenous tianeptine can effectively prevent or counteract opioid-induced respiratory depression in humans".12 With alfentanil, ventilation at the primary endpoint was 13.7 l/min after placebo and 17.9 l/min after 50 mg of tianeptine, a difference reported as "P = 0.070".12 In the intravenous study, tianeptine over 500 to 2,000 ng/mL "did not stimulate ventilation but instead worsened remifentanil-induced respiratory depression" (mean difference 5.3 l/min; 95% CI, 2.5 to 8.2).12 The authors conclude that "Neither oral nor intravenous tianeptine were respiratory stimulants".12 The PubMed record lists the types "Research Support, Non-U.S. Gov't" and "Research Support, U.S. Gov't, P.H.S." and gives no stated limitations; these were healthy volunteers, not people with depression.12
Doses reported in studies and on labels
No tianeptine label was identified in DailyMed: a search for "tianeptine" returned 0 labels, so the table draws on trials, a review and a regulator's description of misuse reports. The app's typical dose of 12.5 to 37.5 mg/day sits beside a range of 25 to 50 mg/day investigated in the 2001 review and used in the 1997 placebo-controlled study, and 12.5 mg three times daily in the NCT04249596 registry entry.2,9,7
| Source | Setting | Dose reported | Duration, comparator and n |
|---|---|---|---|
| Wagstaff and colleagues, 2001 review2 | Patients with depressive disorders | 25 to 50 mg/day investigated | Not given in the record; review of trials |
| Nishio and colleagues, 2024 review3 | 12 healthy volunteers (6 men, 6 women) | Single oral 12.5 mg sodium salt | Single dose; no comparator |
| Zheng and Kim, 20148 | 40 healthy Korean men | One 12.5 mg tablet per period | Crossover with 7-day washout against branded Stablon |
| Costa e Silva and colleagues, 19979 | 126 out-patients with depression | 25-50 mg/day, mean 37.5 mg/day, oral | 42 days against placebo |
| Kauer-Sant'Anna and colleagues, 201910 | Bipolar disorder, 69 randomised responders | 37.5 mg/day adjunctive | 24 weeks against placebo, after 8 weeks open-label |
| Registry NCT042495967 | 38 adults with treatment-resistant depression | 12.5 mg three times daily, oral | 8 weeks, open-label, no comparator |
| Registry NCT0568640811 | 132 adults with major depressive disorder | TNX-601 ER 39.4 mg once daily, oral | 6 weeks against placebo |
| Algera and colleagues, 202212 | Healthy volunteers | Oral 37.5, 50 and 100 mg (8 subjects); intravenous infusions targeting 400, 1,000, 1,500 and 2,000 ng/mL over 15 minutes each (15 volunteers) | Crossover against placebo, with alfentanil or remifentanil |
| FDA alert, current as of 05/08/20254 | Case reports of US consumers | Daily doses of 1.3 to 250 times (50 mg to 10,000 mg) the daily dose typically recommended in labeled foreign drug products | Case reports; no comparator |
Side effects reported
The 2001 review lists the most common adverse effects of tianeptine in depression as "nausea, constipation, abdominal pain, headache, dizziness and changes in dreaming".2 The same review says "Hepatoxicity is rare" and describes a "low propensity for abuse", statements made in 2001 and before the US misuse reports described below.2 In the trials above, headaches were more frequent with tianeptine than placebo in Costa e Silva's study, the bipolar trial reported no higher risk of manic switch, NCT04249596 listed one serious event, headache in 2 and somnolence in 3 of 38, and UPLIFT listed seizure, generalized tonic-clonic seizure and syncope among serious events on TNX-601 ER (one dermatomyositis event on placebo) and nausea in 7 of 64 on TNX-601 ER against 3 of 68 on placebo.9,10,7,11 In healthy volunteers, intravenous tianeptine at 500 to 2,000 ng/mL worsened remifentanil-induced respiratory depression.12 The FDA states it "continues to receive severe adverse event reports" after use of Neptune's Fix products, "including seizures, loss of consciousness and death", and that tianeptine products "may also interact, in life-threatening ways, with other medications a consumer may be taking".4
Deeper analysis: Quadir and colleagues, US poison centers, 2015 to 2023
Quadir and colleagues, writing in the Journal of Medical Toxicology in 2025, "analyzed cases involving tianeptine reported to the National Poison Data System from 2015 to 2023".13 They report 892 single-substance tianeptine exposures, a rate increase of 1,400% from 2015 to 2023, with most exposures associated with moderate (51.5%) or major (12.0%) effects and 40.1% requiring medical admission, including 22.9% to a critical care unit.13 The authors state there were no fatalities in the study, and that tianeptine-related deaths have been reported elsewhere.13 "Tianeptine abuse accounted for 40.1% of exposures" and "Withdrawal accounted for 22.5% of tianeptine exposures".13 Alabama regulated tianeptine as a controlled substance in 2021, and its exposure rate fell by 74.6% from 2021 to 2023 while the rate in other southern states continued to increase; the authors write that, despite the limitations of an observational study design, this suggests an association with Alabama's law.13 The authors list limitations: "Not all tianeptine exposures are reported to PCs; therefore, NPDS data underestimate the true number of exposures", "Tianeptine dose was not accounted for in this study", and "Reported exposures do not necessarily represent a poisoning or overdose".13 The first author received a student scholar stipend from the Child Injury Prevention Alliance, which the paper says was not involved in the study's design, analysis or manuscript, and the authors declare no conflicts of interest.13
Deeper analysis: Hershey and colleagues, Tennessee, 2021 to 2023
Hershey and colleagues of the Tennessee Department of Health used the ESSENCE, SUDORS and NFLIS databases and report "50 tianeptine-involved emergency department visits, 6 tianeptine-involved fatal overdoses, and 19 tianeptine substance seizures".14 Among the 50 visits, triage notes mentioned withdrawal from tianeptine in 17 (34.0%).14 The authors write that "no deaths were caused by tianeptine alone" and that fentanyl was detected in 83.3% of the deaths.14 In 5 of the 6 fatal cases tianeptine was listed as a cause of death along with other substances.14 They conclude that all fatal cases "involved other substances, suggesting tianeptine plays a role in polysubstance use".14 The work was supported by a grant from the Centers for Disease Control and Prevention, whose funding agency "had no role in the design, analysis, or interpretation of the findings", and the authors declare no competing interests; a search of the article text for the word "limitation" returned nothing.14
Bloodwork and markers
Sources in this part
The app lists liver enzymes (ALT, AST) as the marker to monitor for tianeptine. The only liver statement among the records read is the 2001 review's "Hepatoxicity is rare", which concerns its use in depression.2 The poison-center study states that "Toxicological testing for tianeptine is not routinely done, and if done, was not reported in the NPDS database".13 The registry entries and journal records read for tianeptine do not report liver enzyme results.
Regulatory and anti-doping status
The FDA's alert, content current as of 05/08/2025, says tianeptine "is not generally recognized as safe for use in food, and does not meet the statutory definition of a dietary ingredient", while being marketed as a "research chemical", a "nootropic" cognitive enhancer, or a dietary supplement.4 The FDA's page is titled "FDA warns consumers not to purchase or use any tianeptine product due to serious risks", and records a letter of 11 January 2024 urging retailers to stop selling Neptune's Fix and other tianeptine products.4 Hershey and colleagues write that tianeptine "is not a federally controlled substance, but became a schedule II substance in Tennessee on July 1, 2022".14 Quadir and colleagues state that Alabama became the first southern state to regulate it as a controlled substance in April 2021 and that "at least 12 US states have designated tianeptine as a controlled substance as of January 2024".13 The app's notes name Michigan, Alabama, Tennessee, Kentucky, Mississippi, Georgia, Indiana, Ohio and Florida as states where it is banned or scheduled; of these, the sources cited above name Alabama and Tennessee. Tianeptine is not named in the 2026 WADA Prohibited List text that was searched for the word "tianeptine"; the list's S7 narcotics class names substances such as buprenorphine, fentanyl and its derivatives, morphine, tramadol, methadone and oxycodone.15
What is not known
No tianeptine label was identified in DailyMed (a search for "tianeptine" returned 0 labels), so no US prescribing information is available to set beside the app's figures. The placebo-controlled results described above point in different directions: Costa e Silva reports better MADRS scores with tianeptine, the bipolar maintenance trial reports no differences in time to intervention or depression scores, and the UPLIFT entry posts MADRS changes of -12.7 and -12.8 with no p-value or interval.9,10,11 The mouse result of no tolerance or withdrawal sits beside poison-center data in which withdrawal accounted for 22.5% of exposures, and the records read do not address the difference.6,13 Doses taken in misuse are known only through case reports cited by the FDA, and the poison-center study did not account for dose.4,13 The app's notes give a sulfate extended-release range of 25-50 mg/day and a duration of about 8 hours, and the records read give no figure to set beside them. Whether the receptor findings in cells and mice account for the effects reported in people is stated by the authors as a hypothesis.5
Frequently asked questions
What is the half-life of tianeptine?
Royer and colleagues report a mean elimination half-life of 2.5 ± 1.1 hours in healthy volunteers, and the app lists 2.5 hours.1
What is the bioavailability of tianeptine?
Absolute oral bioavailability is reported as 99 +/- 29% in healthy subjects, and the app lists 99%.1
How long does tianeptine take to reach its peak level?
Royer and colleagues report maximum plasma concentration by the first hour after dosing (0.94 +/- 0.47 h), and the app lists about 1 hour.1
Which receptor does tianeptine act on?
Is tianeptine approved by the FDA?
Is tianeptine banned by WADA?
Is tianeptine a controlled substance?
It is not a federally controlled substance in the United States, according to Hershey and colleagues, who report that it became a schedule II substance in Tennessee on July 1, 2022.14 Quadir and colleagues state that at least 12 US states had designated it a controlled substance as of January 2024.13
Has tianeptine been tested against placebo in depression?
Costa e Silva and colleagues reported better final MADRS scores with tianeptine than placebo in 126 out-patients over 42 days.9 In a bipolar maintenance trial there were no differences from placebo in time to intervention or depression scores, and the UPLIFT registry entry posts MADRS changes of -12.7 with TNX-601 ER and -12.8 with placebo.10,11
What side effects are reported with tianeptine?
Guides, tools and comparisons
References
- Royer RJ, et al. Pharmacokinetic and metabolic parameters of tianeptine in healthy volunteers and in populations with risk factors. Clin Neuropharmacol 1988. PMID 3180120
- Wagstaff AJ, et al. Tianeptine: a review of its use in depressive disorders. CNS Drugs 2001. PMID 11463130
- Nishio Y, et al. Classics in Chemical Neuroscience: Tianeptine. ACS Chem Neurosci 2024. PMC11587517
- US Food and Drug Administration. FDA warns consumers not to purchase or use any tianeptine product due to serious risks. Drug alerts and statements, content current as of 8 May 2025. FDA alert
- Gassaway MM, et al. The atypical antidepressant and neurorestorative agent tianeptine is a μ-opioid receptor agonist. Transl Psychiatry 2014. PMC4119213
- Samuels BA, et al. The Behavioral Effects of the Antidepressant Tianeptine Require the Mu-Opioid Receptor. Neuropsychopharmacology 2017. PMC5561344
- ClinicalTrials.gov. NCT04249596. Tianeptine for Treatment Resistant Depression. Registry entry with results, verified 2026-01. NCT04249596
- Zheng R, Kim BH. Pharmacokinetic and bioequivalence assessment of two formulations of tianeptine sodium in healthy male volunteers. Int J Clin Pharmacol Ther 2014. PMID 25109511
- Costa e Silva JA, et al. Placebo-controlled study of tianeptine in major depressive episodes. Neuropsychobiology 1997. PMID 9018020
- Kauer-Sant'Anna M, et al. Adjunctive tianeptine treatment for bipolar disorder: A 24-week randomized, placebo-controlled, maintenance trial. J Psychopharmacol 2019. PMID 30835152
- ClinicalTrials.gov. NCT05686408. Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD). Registry entry with results, verified 2025-01. NCT05686408
- Algera H, et al. Respiratory Effects of the Atypical Tricyclic Antidepressant Tianeptine in Human Models of Opioid-induced Respiratory Depression. Anesthesiology 2022. PMID 35867853
- Quadir M, et al. Tianeptine Exposures Reported to United States Poison Centers, 2015–2023. J Med Toxicol 2025. PMC11706824
- Hershey HL, et al. Tianeptine-involved emergency department visits, fatal overdoses, and substance seizures in Tennessee, 2021–2023. Drug Alcohol Depend Rep 2024. PMC11386040
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list